Headquartered in San Francisco, CA Fiscal year ends December NYSE: HIMS hims.com
Hims & Hers Health, Inc. is a global health and wellness platform that provides access to personalized care through its websites and mobile applications. The company offers prescription and non-prescription products and services across multiple health specialties, including medical consultation services, membership-based access, post-consultation service support, and laboratory testing. A substantial majority of its online sales are subscription-based, with customers billed on a recurring basis for automatic product and service delivery. Following its acquisition of Eucalyptus, the company has significantly expanded its international presence. Hims & Hers is investing in a doctor-led AI clinical engine to enhance care delivery and is undergoing a strategic shift in its U.S. weight loss offering toward branded GLP-1 medications. The company trades on the NYSE under the ticker HIMS. Updated
A 9.1% run to $29.34 adds roughly $550 million to this $6.6 billion telehealth name in a single session. Moves this size are where the stock's whole month gets decided, so keep an eye on whether it holds into the next open.
A fresh Form 3 from the person who signs off on the books lands as Hims & Hers fights Novo Nordisk in court and the FDA tightens compounded GLP-1 rules. Accounting leadership changes at a $6.6 billion company whose revenue recognition is under a microscope are worth tracking filing by filing.
All three major US wireless carriers closed down double digits on the same day, a rare sweep for names usually bought as defensive income. Moderna's 13.8% gain topped the board on the other side.
An 8.8% intraday run adds roughly half a billion dollars of market value to a $6.9 billion company in a single session. Moves this size rarely settle quietly here, so keep an eye on the stock into the close.
The tape spread nearly 12 points wide at the close: C3.ai finished up 6.43% at $11.01 while Moderna gave back 5.52%. Enterprise tech names took the top four gainer slots, and the losers skew toward high-beta momentum.
Travel took the worst of Wednesday's close, with Expedia down 7.72% and Airbnb close behind at 7.56%. Software ran the other way: Palo Alto Networks led all gainers at 4.87%, with Palantir back near $192.
Arista Networks closed up 6.2%, the best move in a 111-stock priority list where hardware names took the top four gainer slots. Snap fell 8% to $5.45, the day's steepest decline.
The damage at Monday's close ran deeper than the gains: Applied Optoelectronics shed 11.6% while the best performer, AMC Entertainment, managed 6.08%. Four of the five worst names lost more than 7% in a single session.
Futu Holdings closed up 9.75%, the biggest move in a 110-stock priority list where five names finished higher by 5% or more. The downside was far tamer: only Cipher Mining lost more than 4%.
Hims and Hers Health heads into Q2 earnings carrying a brutal Q1 miss, margin compression, and a prediction market giving better than even odds on another stumble. Whether tonight's numbers vindicate the…
Thomas Richmond Hims and Hers has 2.6 million subscribers, a battered stock price, and a CEO buying shares instead of signaling an exit. That combination puts a very specific list of giants on alert,…
Scott Galloway and Ed Elson laid out the math on Prof G Markets and it should make every fast food shareholder uneasy: roughly 30 million Americans, about 1 in 8 US adults,…
Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector’s short history, and bargain hunters are circling the…
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product…
Hims & Hers Health (NYSE:HIMS) absorbed another analyst downgrade. Bank of America cut its price objective on Hims & Hers stock to $30 from $32, while keeping a Neutral rating. The firm…
David Moadel Shares of Hims & Hers Health (NYSE:HIMS) are under pressure after JPMorgan trimmed its price target on the consumer telehealth name following a messy first quarter. The firm lowered its price target…
David Moadel Live Updates HIMS Q1 Earnings Coverage Wrap-Up4:25pm ETThat wraps up our initial coverage of Hims and Hers Health’s Q1 results. Thank you for stopping by! Check out management’s earnings call at 5…
Thomas Richmond Hims & Hers Health (NYSE:HIMS) just picked up a high-profile endorsement. JPMorgan analyst Cory Carpenter initiated coverage with an Overweight rating and a $35 price target, framing the telehealth platform’s recent Novo…
The GLP-1 weight-loss category exploded into a multi-billion-dollar opportunity that blends medication access with ongoing patient support. This morning, Amazon‘s (NASDAQ:AMZN | AMZN Price Prediction) One Medical platform rolled out a national…
Rich Duprey Hims & Hers Health (NYSE:HIMS) shares are up 9% in early trading Monday, climbing from $28.82 to $31 and change as investors pile into the stock ahead of a May 11 earnings…
The S&P 500 (^GSPC) crossed 7,000 for the first time in history this week, closing at 7,022.95 on Wednesday before pushing to 7,041.28 on Thursday. Futures are pointing higher Friday as President…
Hims & Hers Health (NYSE:HIMS) just got a fresh look from Bank of America, which raised its price target on the stock to $25 from $21 while maintaining a Neutral rating. The…
David Moadel Hims & Hers Health (NYSE:HIMS) looked like a fallen growth star earlier this year. The telehealth platform was hammered by the FDA’s aggressive crackdown on compounded GLP-1 drugs, complete with warning letters…
Rich Duprey Two healthcare names are drawing fresh analyst attention this week as Wall Street recalibrates around a landmark GLP-1 truce and a fertility benefits company navigating a murky 2026 outlook. Barclays analyst Glen…
Hims & Hers Health, Inc. is a global health and wellness platform that provides access to personalized care through its websites and mobile applications.
The Wall Street consensus 12-month price target for HIMS is $31.15.
